-
1 week ago | 
pharmacytimes.com | Gillian McGovern
In a recent study published in JAMA Network Open, childhood cancer survivors (CCS) were found to be at an increased risk for developing chronic kidney disease (CKD) compared with a hospitalized cohort. In addition to CKD, the survivors were also found to have an increased risk of hypertension.
-
1 week ago | 
pharmacytimes.com | Gillian McGovern
This is an ongoing story. The FDA approved the new drug application for hydrocortisone oral solution (Khindivi; Eton Pharmaceuticals) as a replacement therapy in pediatric patients with adrenocortical insufficiency who are 5 years of age and older. This decision is the first oral solution formulation of hydrocortisone to be FDA-approved, according to a news release from the manufacturers.
-
1 week ago | 
pharmacytimes.com | Gillian McGovern
Authors of a study published in Science Advances discovered that blocking cell death effector proteins may rescue cells from degeneration. This finding—which involves the small molecule, WEHI-3773, which can effectively block cell death—may be leveraged to develop new treatments for neurodegenerative disorders such as Parkinson and Alzheimer disease.1There is a need for new drugs to target the apoptosis (cell death) pathway at multiple levels and more effectively, the study authors wrote.
-
1 week ago | 
pharmacytimes.com | Gillian McGovern
The FDA approved an inhalation powder formulation of treprostinil (formerly LIQ861, Yutrepia; Liquidia Corporation) for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The approval was supported by findings from the phase 3 INSPIRE trial (NCT03399604).1,2Yutrepia is an investigational, inhaled dry-powder formulation of treprostinil delivered through a low-resistance, palm-sized device.
-
1 week ago | 
pharmacytimes.com | Gillian McGovern
Findings from a recent study published in Cellular and Molecular Life Sciences show that the growth arrest and DNA damage inducible 45A (GADD45A) has an important role within the heart. It may prevent inflammation, fibrosis, and apoptosis, indicating a potential to preserve cardiac function and performance.
-
2 weeks ago | 
pharmacytimes.com | Gillian McGovern
In the chronic kidney disease (CKD) space, existing prognostic tools demonstrate below-standard quality performance in a validation cohort of older patients, said study investigators in Internal Medicine Journal. They emphasized that further research is needed to develop a specific tool that is more applicable to the older population with advanced CKD.1Kidney disease occurs when a patient’s kidneys are not functioning properly and cannot filter waste, leading to buildup in the blood.
-
2 weeks ago | 
pharmacytimes.com | Gillian McGovern
This is an ongoing story. The FDA approved the supplemental new drug application (sNDA) for roflumilast (Zoryve; Arcutis Biotherapeutics) topical foam 0.3% for the treatment of adult and pediatric patients aged 12 years and older with plaque psoriasis of the scalp and body.
-
2 weeks ago | 
pharmacytimes.com | Gillian McGovern
Results from the phase 3 REAL8 clinical trial (NCT05330325) demonstrate that once-weekly somapacitan (Sogroya; Novo Nordisk) was noninferior to the once-daily growth hormone somatropin (Norditropin; Novo Nordisk) in improving yearly growth rate in prepubertal children born small for gestational age (SGA), with Noonan syndrome (NS), or with idiopathic short stature (ISS).
-
2 weeks ago | 
pharmacytimes.com | Gillian McGovern
Women who experience infertility are more likely to develop heart and blood vessel conditions later in life, with younger women and those who undergo fertility treatments at greater risk, according to study results that were presented at the European Society of Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE) 2025 Joint Congress.
-
2 weeks ago | 
pharmacytimes.com | Gillian McGovern
Positive results from the phase 3 GLISTEN trial (NCT04950127) show that linerixibat (GSK2330672; GSK), when used in adult patients with cholestatic pruritus and primary biliary cholangitis (PBC), met its primary end point as well as key secondary end points.1,2 Full data were presented in a late-breaker oral presentation at the 2025 European Association for the Study of the Liver (EASL) Congress, according to a GSK news release.1 PBC is a rare autoimmune cholestatic liver disease in which...
